21 October 2024
21 October 2024
An 800% increase in licensing deal values indicates growing confidence in mRNA technology.
A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.
The FDA's decision is grounded in the outcomes of the Phase III SPOTLIGHT and GLOW clinical trials.
While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.
The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz鈥檚 path to market.
Charles River will act as the contract development and manufacturing organisation for FibroBiologics.
An FDA AdCom in September recommended against full approval for Ocaliva by a 13-1 vote for the treatment of primary biliary cholangitis.
BRENZAVVY is an FDA-approved oral SGLT2 inhibitor.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics鈥� Rebyota and Seres Therapeutics鈥� Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics鈥� Rebyota and Seres Therapeutics鈥� Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics鈥� Rebyota and Seres Therapeutics鈥� Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics鈥� Rebyota and Seres Therapeutics鈥� Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
GlobalData's latest report assesses the current landscape of microbiome-based therapeutics in the seven major markets. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics鈥� Rebyota and Seres Therapeutics鈥� Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions.
Give your business an edge with our leading industry insights.
